Hospital
W.A. Foote Memorial Hospital
W.A. Foote Memorial Hospital was paid $41.32M by Medicaid between Jan 2018 and Dec 2024, across 472 billing codes. Its largest line is 99285, emergency room visit (most serious) — 21% of everything it billed.
33Billing provider infoW.A. FOOTE MEMORIAL HOSPITAL
JACKSON, MI 49201
JACKSON, MI 49201
33aNPI1053403402assigned 09/29/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$41.32M
24GClaims1,422,634
24DCodes billed472
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#30 of 86
Median peer was paid$21.55M
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DAMSCHRODER, ROBIN controls 14+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 62,914 | $3.16M | |
| 2019 | 156,328 | $4.00M | |
| 2020 | 162,642 | $4.09M | |
| 2021 | 228,193 | $6.10M | |
| 2022 | 247,473 | $6.89M | |
| 2023 | 279,065 | $8.05M | |
| 2024incomplete | 286,019 | $9.04M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 28,797 | 25,527 | $8.52M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 10% | 94,983 | 75,283 | $4.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.9% | 15,845 | 14,502 | $2.87M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.4% | 20,981 | 19,696 | $2.64M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.8% | 17,302 | 14,996 | $1.58M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.3% | 12,366 | 11,883 | $969K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.0% | 2,057 | 2,045 | $817K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.8% | 2,576 | 2,554 | $761K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 16,003 | 12,613 | $701K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 10,773 | 10,400 | $609K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.4% | 28,292 | 27,686 | $581K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.3% | 27,091 | 26,549 | $555K |
460 more codes
| H0005 | Alcohol and/or drug services; group counseling by a clinician | 1.3% | 10,961 | $522K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 4,448 | $502K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 5,783 | $483K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 4,619 | $449K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.0% | 21,227 | $428K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 4,142 | $419K |
| G0378 | Hospital observation service, per hour | 1.0% | 3,263 | $418K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 11,918 | $417K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,800 | $403K |
| 80061 | Lipid panel | <1% | 31,248 | $369K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,190 | $343K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 17,819 | $337K |
| 90837 | Psychotherapy session, about an hour | <1% | 3,081 | $315K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,066 | $313K |
| 80053 | Comprehensive metabolic panel | <1% | 63,758 | $305K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 32,395 | $302K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,778 | $260K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 77,275 | $227K |
| 81513 | <1% | 2,459 | $219K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 470 | $212K |
| 20610 | <1% | 1,651 | $208K | |
| 87481 | <1% | 6,819 | $203K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 613 | $197K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13,853 | $193K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,328 | $192K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 9,744 | $186K |
| 97161 | <1% | 3,184 | $168K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 28,093 | $163K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,830 | $160K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,238 | $154K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 254 | $151K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,911 | $146K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,893 | $143K |
| 76830 | Ultrasound, transvaginal | <1% | 2,603 | $143K |
| H2027 | Psychoeducational service, per 15 minutes | <1% | 3,975 | $139K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,270 | $138K |
| 93975 | <1% | 1,277 | $135K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,127 | $132K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,372 | $129K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,555 | $124K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,895 | $124K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,236 | $119K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,391 | $108K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 6,536 | $105K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 547 | $103K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 4,796 | $101K |
| H0001 | Alcohol and/or drug assessment | <1% | 734 | $99K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,926 | $99K |
| 64721 | <1% | 124 | $94K | |
| 80074 | <1% | 3,326 | $92K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 2,682 | $91K |
| 76801 | <1% | 1,606 | $91K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 428 | $91K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,876 | $90K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,779 | $89K |
| 90677 | <1% | 638 | $88K | |
| 87511 | <1% | 4,136 | $87K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 39 | $87K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,494 | $83K |
| 85027 | <1% | 25,634 | $83K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 31,492 | $81K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 280 | $76K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,182 | $74K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 17,050 | $71K |
| 86803 | <1% | 7,994 | $68K | |
| 86780 | <1% | 8,049 | $68K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,680 | $67K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,572 | $66K |
| 84702 | <1% | 11,731 | $64K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,045 | $60K |
| 82728 | <1% | 7,135 | $59K | |
| 82607 | <1% | 6,427 | $57K | |
| 97165 | <1% | 1,166 | $57K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,251 | $56K |
| 87653 | <1% | 2,546 | $53K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 161 | $52K |
| 87081 | <1% | 14,696 | $50K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 810 | $50K |
| 59025 | Fetal non-stress test | <1% | 586 | $49K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,593 | $49K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 125 | $47K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,225 | $47K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 584 | $46K |
| 83970 | <1% | 1,782 | $44K | |
| 84439 | <1% | 8,047 | $43K | |
| 86003 | <1% | 503 | $40K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 675 | $40K |
| 83880 | <1% | 2,546 | $39K | |
| 83550 | <1% | 7,172 | $38K | |
| 87634 | <1% | 2,089 | $37K | |
| 93971 | <1% | 750 | $37K | |
| Q3014 | Telehealth originating site facility fee | <1% | 2,219 | $36K |
| 86900 | <1% | 7,000 | $36K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,539 | $36K |
| 76770 | <1% | 673 | $35K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 612 | $35K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 84 | $34K |
| 85610 | <1% | 16,465 | $34K | |
| 96367 | <1% | 1,044 | $34K | |
| 76642 | <1% | 841 | $33K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 815 | $33K |
| 88142 | <1% | 2,489 | $32K | |
| 87077 | <1% | 5,532 | $32K | |
| 86480 | <1% | 836 | $32K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 341 | $32K |
| 84403 | <1% | 1,948 | $31K | |
| 73630 | <1% | 3,850 | $30K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,920 | $30K |
| G0008 | Administration of influenza virus vaccine | <1% | 2,771 | $30K |
| 83540 | <1% | 7,654 | $30K | |
| 84146 | <1% | 2,483 | $30K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 590 | $29K |
| 82570 | <1% | 9,140 | $28K | |
| 82746 | <1% | 3,281 | $28K | |
| 83735 | <1% | 14,416 | $28K | |
| 86235 | <1% | 733 | $28K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 314 | $27K |
| 87529 | <1% | 873 | $27K | |
| 87186 | <1% | 5,533 | $27K | |
| 86850 | <1% | 7,280 | $26K | |
| 81001 | <1% | 25,502 | $26K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 2,169 | $26K |
| 82043 | <1% | 7,147 | $25K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,218 | $25K |
| 73610 | <1% | 2,856 | $25K | |
| 73564 | <1% | 1,149 | $25K | |
| 62323 | <1% | 78 | $25K | |
| 70496 | <1% | 367 | $25K | |
| 72100 | <1% | 1,162 | $24K | |
| 71271 | <1% | 415 | $24K | |
| 90686 | <1% | 1,761 | $24K | |
| 76536 | <1% | 470 | $23K | |
| 83001 | <1% | 2,004 | $23K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 769 | $23K |
| 87340 | <1% | 3,992 | $23K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 183 | $22K |
| 87631 | <1% | 768 | $22K | |
| 91320 | <1% | 201 | $21K | |
| 73130 | <1% | 3,084 | $20K | |
| 87070 | <1% | 4,401 | $20K | |
| 90682 | <1% | 349 | $19K | |
| 86140 | <1% | 7,144 | $19K | |
| 86039 | <1% | 2,793 | $19K | |
| 80076 | <1% | 3,763 | $18K | |
| 87522 | Neg quan hep c or qual rna | <1% | 718 | $18K |
| 71250 | <1% | 378 | $18K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 293 | $17K |
| 90651 | <1% | 180 | $17K | |
| 83655 | <1% | 2,150 | $17K | |
| 73030 | <1% | 1,791 | $16K | |
| 29075 | <1% | 132 | $16K | |
| 72110 | <1% | 737 | $16K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,349 | $16K |
| 84112 | <1% | 345 | $15K | |
| 73110 | <1% | 1,721 | $15K | |
| 81025 | <1% | 10,158 | $15K | |
| 74018 | <1% | 940 | $14K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,829 | $14K |
| 73562 | <1% | 1,057 | $14K | |
| 20611 | <1% | 94 | $14K | |
| 73502 | <1% | 1,141 | $13K | |
| 36591 | <1% | 332 | $13K | |
| 88342 | <1% | 559 | $12K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 184 | $12K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 687 | $12K |
| 82274 | <1% | 1,539 | $12K | |
| 86160 | <1% | 832 | $12K | |
| 83020 | <1% | 1,702 | $11K | |
| 70491 | <1% | 117 | $11K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 294 | $11K |
| 73140 | <1% | 900 | $11K | |
| 93017 | <1% | 164 | $11K | |
| 52000 | <1% | 62 | $11K | |
| 64400 | <1% | 94 | $11K | |
| 86200 | <1% | 1,411 | $11K | |
| 86762 | <1% | 1,370 | $11K | |
| 85652 | <1% | 7,046 | $10K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 87 | $10K |
| 72050 | <1% | 298 | $10K | |
| 82731 | <1% | 346 | $10K | |
| 82565 | <1% | 3,230 | $10K | |
| 86255 | <1% | 1,179 | $10K | |
| 85730 | <1% | 5,738 | $10K | |
| 87088 | <1% | 2,325 | $10K | |
| 73560 | <1% | 1,976 | $10K | |
| 82105 | <1% | 946 | $9K | |
| 82947 | <1% | 3,915 | $9K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 158 | $9K |
| 94726 | <1% | 67 | $9K | |
| 83002 | <1% | 745 | $9K | |
| 83525 | <1% | 1,200 | $9K | |
| 83690 | <1% | 11,015 | $9K | |
| 72141 | <1% | 74 | $9K | |
| 73080 | <1% | 983 | $8K | |
| 83013 | <1% | 187 | $8K | |
| 87808 | <1% | 1,033 | $8K | |
| 82784 | <1% | 557 | $8K | |
| 84425 | <1% | 586 | $8K | |
| 82962 | <1% | 10,319 | $8K | |
| 81003 | <1% | 7,195 | $8K | |
| 86431 | <1% | 2,281 | $8K | |
| 86901 | <1% | 6,986 | $8K | |
| 90480 | <1% | 235 | $7K | |
| 90656 | <1% | 623 | $7K | |
| 82248 | <1% | 9,774 | $7K | |
| 76882 | <1% | 194 | $7K | |
| 70486 | <1% | 267 | $7K | |
| 87205 | <1% | 3,248 | $7K | |
| 83516 | <1% | 482 | $7K | |
| 82670 | <1% | 384 | $7K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 30 | $6K |
| 73020 | <1% | 679 | $6K | |
| 86706 | <1% | 956 | $6K | |
| 84550 | <1% | 2,350 | $6K | |
| 84484 | <1% | 9,779 | $6K | |
| 87420 | <1% | 1,557 | $6K | |
| G0451 | Development testing, with interpretation and report, per standardized instrument form | <1% | 182 | $6K |
| 10060 | <1% | 71 | $6K | |
| 77066 | Tomosynthesis, mammo | <1% | 99 | $5K |
| 82550 | <1% | 1,994 | $5K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 408 | $5K |
| 64450 | <1% | 77 | $5K | |
| 86376 | <1% | 584 | $5K | |
| 84153 | <1% | 425 | $5K | |
| 97162 | <1% | 113 | $5K | |
| 82805 | <1% | 1,695 | $5K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $5K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 277 | $4K |
| 84156 | <1% | 2,183 | $4K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 12 | $4K |
| 64615 | <1% | 38 | $4K | |
| 51798 | <1% | 1,582 | $4K | |
| 87210 | <1% | 1,230 | $4K | |
| 73100 | <1% | 300 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,736 | $4K |
| 90750 | <1% | 30 | $4K | |
| 84481 | <1% | 399 | $4K | |
| 73590 | <1% | 571 | $4K | |
| 0054A | <1% | 131 | $4K | |
| 87625 | <1% | 176 | $4K | |
| 85018 | <1% | 2,614 | $4K | |
| 82533 | <1% | 361 | $4K | |
| 0124A | <1% | 153 | $4K | |
| 99406 | <1% | 290 | $4K | |
| 80069 | <1% | 661 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,468 | $4K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 428 | $3K |
| 87147 | <1% | 729 | $3K | |
| 84460 | <1% | 1,073 | $3K | |
| 86038 | <1% | 457 | $3K | |
| 88304 | <1% | 951 | $3K | |
| 85379 | <1% | 1,937 | $3K | |
| 83615 | <1% | 1,061 | $3K | |
| 0001A | <1% | 85 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 65 | $3K |
| 97760 | <1% | 80 | $3K | |
| 85007 | <1% | 1,956 | $3K | |
| 84100 | <1% | 2,716 | $3K | |
| 87899 | <1% | 286 | $2K | |
| 84520 | <1% | 994 | $2K | |
| 90670 | <1% | 541 | $2K | |
| 72072 | <1% | 117 | $2K | |
| 93970 | <1% | 28 | $2K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 216 | $2K |
| 92551 | <1% | 337 | $2K | |
| 87045 | <1% | 399 | $2K | |
| 0004A | <1% | 72 | $2K | |
| 20550 | <1% | 15 | $2K | |
| 87046 | <1% | 399 | $2K | |
| 0002A | <1% | 59 | $2K | |
| 80164 | <1% | 356 | $2K | |
| 87040 | <1% | 1,009 | $2K | |
| 73090 | <1% | 421 | $2K | |
| 17110 | <1% | 66 | $2K | |
| 93229 | <1% | 12 | $2K | |
| 86147 | <1% | 37 | $2K | |
| 86696 | <1% | 152 | $2K | |
| 72158 | <1% | 25 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 62 | $2K |
| 72131 | <1% | 69 | $2K | |
| 88341 | <1% | 30 | $2K | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 253 | $2K |
| 84450 | <1% | 557 | $2K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 184 | $2K |
| 86665 | <1% | 71 | $2K | |
| 86704 | <1% | 218 | $2K | |
| 72156 | <1% | 12 | $2K | |
| C1758 | Catheter, ureteral | <1% | 1,245 | $2K |
| 73221 | <1% | 14 | $1K | |
| 72040 | <1% | 128 | $1K | |
| 84165 | <1% | 202 | $1K | |
| 85045 | <1% | 603 | $1K | |
| 70498 | <1% | 353 | $1K | |
| 86695 | <1% | 152 | $1K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $1K |
| 82785 | <1% | 106 | $1K | |
| 11721 | <1% | 142 | $1K | |
| 82677 | <1% | 89 | $1K | |
| 69210 | <1% | 95 | $1K | |
| 83520 | <1% | 91 | $1K | |
| 29125 | <1% | 178 | $1K | |
| 74022 | <1% | 95 | $1K | |
| 83993 | <1% | 81 | $936.75 | |
| 99385 | <1% | 12 | $832.19 | |
| 90461 | <1% | 1,366 | $806.99 | |
| 25600 | <1% | 12 | $798.93 | |
| 84132 | <1% | 322 | $790.71 | |
| 84466 | <1% | 96 | $748.40 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 59 | $719.30 |
| 86336 | <1% | 89 | $710.68 | |
| 86664 | <1% | 71 | $670.24 | |
| 88307 | <1% | 12 | $652.96 | |
| 87324 | <1% | 88 | $632.61 | |
| 87536 | <1% | 14 | $624.93 | |
| 86705 | <1% | 88 | $608.77 | |
| 97116 | <1% | 175 | $587.72 | |
| 82627 | <1% | 43 | $581.51 | |
| 87329 | <1% | 77 | $576.81 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 66 | $550.87 |
| 82525 | <1% | 65 | $531.18 | |
| 81002 | <1% | 304 | $524.51 | |
| 83014 | <1% | 104 | $515.88 | |
| Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | <1% | 65 | $502.29 |
| 96523 | <1% | 22 | $486.84 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,399 | $466.61 |
| 73700 | <1% | 12 | $461.27 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 68 | $444.82 |
| 71101 | <1% | 39 | $444.30 | |
| 84681 | <1% | 38 | $443.76 | |
| 72080 | <1% | 16 | $426.24 | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 25 | $419.36 |
| 86580 | <1% | 93 | $406.93 | |
| 86308 | <1% | 238 | $348.92 | |
| 12001 | <1% | 128 | $346.28 | |
| 82150 | <1% | 92 | $338.39 | |
| 93922 | <1% | 12 | $331.11 | |
| 94010 | <1% | 72 | $329.72 | |
| 84630 | <1% | 41 | $310.20 | |
| 83605 | <1% | 1,368 | $301.97 | |
| 73060 | <1% | 41 | $285.28 | |
| 96380 | <1% | 17 | $274.21 | |
| 82330 | <1% | 38 | $268.04 | |
| 98927 | <1% | 71 | $256.88 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 36 | $240.98 |
| 80178 | <1% | 66 | $237.56 | |
| 82024 | <1% | 12 | $222.15 | |
| 83721 | <1% | 33 | $217.36 | |
| 82077 | <1% | 3,890 | $215.75 | |
| G0010 | Administration of hepatitis b vaccine | <1% | 12 | $194.85 |
| 90734 | <1% | 83 | $166.23 | |
| 86225 | <1% | 22 | $165.91 | |
| 86694 | <1% | 15 | $151.11 | |
| 96127 | <1% | 25 | $146.30 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,037 | $138.37 |
| 73552 | <1% | 42 | $133.24 | |
| 84145 | <1% | 175 | $116.80 | |
| 80143 | <1% | 824 | $116.36 | |
| 72170 | <1% | 58 | $114.60 | |
| 72128 | <1% | 12 | $114.60 | |
| 82951 | <1% | 14 | $112.27 | |
| 86787 | <1% | 13 | $107.43 | |
| 84590 | <1% | 13 | $102.33 | |
| 82977 | <1% | 25 | $98.30 | |
| 73000 | <1% | 12 | $94.72 | |
| 90662 | <1% | 14 | $81.23 | |
| 85347 | <1% | 13 | $79.98 | |
| 90723 | <1% | 616 | $65.77 | |
| 85384 | <1% | 13 | $61.29 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 21 | $60.59 |
| 73620 | <1% | 12 | $51.99 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 12 | $48.18 |
| 73600 | <1% | 23 | $48.14 | |
| 82010 | <1% | 176 | $47.51 | |
| 87075 | <1% | 26 | $39.42 | |
| 85049 | <1% | 15 | $35.44 | |
| 82952 | <1% | 14 | $34.29 | |
| 86593 | <1% | 13 | $27.00 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 155 | $16.74 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,872 | $12.25 |
| 90681 | <1% | 135 | $7.00 | |
| 90648 | <1% | 609 | $7.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,777 | $5.74 |
| 80179 | <1% | 756 | $5.25 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 36 | $4.07 |
| J3490 | Unclassified drugs | <1% | 2,335 | $1.41 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 221 | $1.05 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 9,034 | $0.43 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,647 | $0.36 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,195 | $0.26 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,431 | $0.07 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,521 | $0.04 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 263 | $0.00 |
| 96376 | 0% | 3,408 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 511 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 130 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 3,512 | $0.00 |
| 96368 | 0% | 82 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 331 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 286 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 229 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 475 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 1,051 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 1,201 | $0.00 |
| C1769 | Guide wire | 0% | 533 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 526 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 677 | $0.00 |
| 95886 | 0% | 101 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 38 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 133 | $0.00 |
| 76870 | 0% | 93 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 450 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 92 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 384 | $0.00 |
| 64415 | 0% | 44 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 57 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 157 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 13 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 12 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 137 | $0.00 |
| 90647 | 0% | 91 | $0.00 | |
| 90696 | 0% | 32 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 236 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 563 | $0.00 |
| 90716 | 0% | 29 | $0.00 | |
| 90381 | 0% | 13 | $0.00 | |
| 91305 | 0% | 145 | $0.00 | |
| 12002 | 0% | 12 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 12 | $0.00 |
| 99152 | 0% | 561 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 464 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 3,596 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 831 | $0.00 |
| 91300 | 0% | 222 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 535 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 862 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 324 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 284 | $0.00 |
| 90715 | 0% | 929 | $0.00 | |
| 76376 | 0% | 49 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 68 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 59 | $0.00 |
| 94729 | 0% | 82 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 120 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 1,541 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 551 | $0.00 |
| 90633 | 0% | 195 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 584 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 194 | $0.00 |
| 90700 | 0% | 28 | $0.00 | |
| 90710 | 0% | 36 | $0.00 | |
| 91312 | 0% | 82 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 334 | $0.00 |
| C1765 | Adhesion barrier | 0% | 116 | $0.00 |
| 94150 | 0% | 49 | $0.00 | |
| 12011 | 0% | 17 | $0.00 | |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | 0% | 12 | $0.00 |
| 82075 | 0% | 45 | $0.00 | |
| 90707 | 0% | 27 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 227 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 53 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAMSCHRODER, ROBIN (EVP, CHIEF FIN & BUS DEV OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Henry Ford Health System | Detroit, MI | $334.91M |
| Henry Ford Health ST. John Hospital | Chicago, IL | $159.41M |
| Henry Ford Health Providence Hospital | Novi, MI | $72.76M |
| Henry Ford Wyandotte Hospital | Wyandotte, MI | $60.54M |
| Henry Ford Health Macomb Oakland Hospital | Warren, MI | $59.25M |
| Henry Ford Macomb Hospital Corporation | Clinton Twp, MI | $40.96M |
| Henry Ford Health Genesys Hospital | Grand Blanc, MI | $31.39M |
| Henry Ford Health Macomb Oakland Hospital | Madison Heights, MI | $24.76M |
| Henry Ford Health System | West Bloomfield, MI | $19.27M |
| Henry Ford Health Rochester Hospital | Rochester, MI | $11.98M |
| Henry Ford Health River District Hospital | East China, MI | $4.59M |
| W.A. Foote Memorial Hospital | Jackson, MI | $2.11M |
| Henry Ford Health Providence Hospital | Novi, MI | $255K |
| Henry Ford Health ST. John Hospital | Detroit, MI | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.